Seelos Therapeutics, Inc. Total Assets
Seelos Therapeutics, Inc. total assets. Based on the latest financial reports, Seelos Therapeutics, Inc. (SEELQ) holds total assets worth $2.38 Million USD as of June 2024. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Seelos Therapeutics, Inc. stock valuation for the company's overall valuation and market capitalisation.
Total Assets of Seelos Therapeutics, Inc. (2020–2023)
Total assets of Seelos Therapeutics, Inc. from 2020 to 2023. This chart illustrates how Seelos Therapeutics, Inc.'s total assets have evolved over time, based on quarterly financial data. See latest Seelos Therapeutics, Inc. stock price today for real-time trading data and today's change.
Seelos Therapeutics, Inc. - Asset Composition Analysis
Seelos Therapeutics, Inc. Total Assets Breakdown (December 2023)
Seelos Therapeutics, Inc. total assets breakdown as of December 2023. Seelos Therapeutics, Inc.'s total assets of $2.38 Million consist of 99.7% current assets and 0.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 55.3% |
| Accounts Receivable | $763.00K | 14.1% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2020–2023)
This chart illustrates how Seelos Therapeutics, Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Seelos Therapeutics, Inc. (SEELQ) working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Seelos Therapeutics, Inc.'s current assets represent 99.7% of total assets in 2023, a decrease from 100.0% in 2020.
- Cash Position: Cash and equivalents constituted 55.3% of total assets in 2023, down from 89.5% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2020.
- Asset Diversification: The largest asset category is accounts receivable at 14.1% of total assets.
Seelos Therapeutics, Inc. Competitors by Total Assets
Key competitors of Seelos Therapeutics, Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
CSL LTD SPON.ADR 2
F:CSJA
|
Germany | €38.45 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
PHARVARIS N.V. EO -12
F:9EN
|
Germany | €301.45 Million |
|
NANOBIOTIX S.A. SP.ADR
F:5NRA
|
Germany | €67.76 Million |
|
Chengdu Easton Biopharmaceuticals Co Ltd
SHG:688513
|
China | CN¥3.82 Billion |
Seelos Therapeutics, Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.08 | 0.21 | 0.21 |
| Quick Ratio | 0.08 | 0.21 | 0.21 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-28.18 Million | $-44.27 Million | $-44.27 Million |
Seelos Therapeutics, Inc. - Advanced Valuation Insights
This section examines the relationship between Seelos Therapeutics, Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -76.2% |
| Total Assets | $5.42 Million |
| Market Capitalization | $58.00 USD |
Valuation Analysis
Below Book Valuation: The market values Seelos Therapeutics, Inc.'s assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Seelos Therapeutics, Inc.'s assets decreased by 76.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Seelos Therapeutics, Inc. (2020–2023)
The table below shows the annual total assets of Seelos Therapeutics, Inc. from 2020 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-12-31 | $5.42 Million | -76.18% |
| 2022-12-31 | $22.75 Million | -72.76% |
| 2021-12-31 | $83.50 Million | +377.31% |
| 2020-12-31 | $17.49 Million | -- |
About Seelos Therapeutics, Inc.
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-004, an gene therap… Read more